Chimerix, Inc. (CMRX)
Stock Price:
$2.89 USD
-0.04 (-1.37%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $2.92 +0.03 (1.04%) Aug 14, 5:09 PM
Key Info
| Market Cap |
179.76M |
| Revenue (ttm) |
11.37M |
| Net Income (ttm) |
-97.67M |
| Shares Out |
62.20M |
| EPS (ttm) |
-1.60 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$2.89 |
| Previous Close |
$2.93 |
| Change ($) |
-0.04 |
| Change (%) |
-1.37% |
| Day's Open |
2.91 |
| Day's Range |
2.81 - 2.94 |
| Day's Volume |
287,732 |
| 52-Week Range |
1.19 - 3.89 |
More Stats
| Market Cap |
179.76M |
| Enterprise Value |
86.11M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
62.20M |
| Float |
44.23M |
| EPS (basic) |
-1.58 |
| EPS (diluted) |
-1.60 |
| FCF / Share |
-1.04 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.19M |
| Short Ratio |
2.45 |
| Short % of Float |
2.39% |
| Beta |
1.90 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
15.81 |
| PB Ratio |
1.96 |
| Revenue |
11.37M |
| Operating Income |
-99.64M |
| Net Income |
-97.67M |
| Free Cash Flow |
-64.34M |
| Net Cash |
93.65M |
| Net Cash / Share |
1.51 |
| Gross Margin |
-228.47% |
| Operating Margin |
-876.46% |
| Profit Margin |
-859.20% |
| FCF Margin |
-566.00% |
| ROA |
-16.69% |
| ROE |
-80.63% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$6.67*
(130.80% upside)
Low
3.00
Current: $2.89
High
10.00
Target: 6.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 12.52 | 7.22 | 4.49 | 5.70 | 10.76 | 4.04 | 4.37 | 33.72 | 12.10 | 1.72 |
| Revenue Growth | 73.49% | 60.57% | -21.19% | -47.02% | 166.39% | -7.55% | -87.04% | 178.65% | 605.6% | - |
| Gross Profit | 12.52 | 7.22 | 4.49 | 5.70 | 10.76 | 4.04 | 4.37 | 33.72 | 12.10 | 1.72 |
| Operating Income | -116 | -71.61 | -72.10 | -77.95 | -118 | -58.87 | -28.62 | -2.78 | -24.99 | -25.30 |
| Net Income | -113 | -69.47 | -70.98 | -76.39 | -117 | -59.31 | -36.45 | -4.41 | -25.59 | -25.46 |
| Shares Outstanding | 55.50 | 48.59 | 46.96 | 46.27 | 43.88 | 33.00 | 19.31 | 1.52 | 1.50 | 1.45 |
| Earnings Per Share | -2.03 | -1.43 | -1.51 | -1.65 | -2.67 | -1.80 | -3.65 | -5.75 | -23.49 | -17.52 |
| Operating Cash Flow | -75.18 | -53.73 | -50.13 | -63.82 | -99.71 | -47.08 | -25.56 | -1.88 | -26.28 | -21.68 |
| Capital Expenditures | -0.16 | -0.18 | -0.15 | -0.84 | -2.39 | -1.02 | -0.19 | -0.13 | -0.32 | -0.12 |
| Free Cash Flow | -75.34 | -53.91 | -50.28 | -64.66 | -102 | -48.10 | -25.75 | -2.00 | -26.60 | -21.80 |
| Cash & Equivalents | 113 | 187 | 152 | 232 | 220 | 235 | 110 | 29.76 | 19.55 | 0.00 |
| Total Debt | 0.20 | 0.14 | 0.22 | 0.44 | 0.35 | 4.30 | 9.87 | 14.62 | 2.60 | - |
| Net Cash / Debt | 113 | 186 | 151 | 232 | 220 | 230 | 100 | 15.14 | 16.95 | 0.00 |
| Assets | 119 | 191 | 235 | 287 | 356 | 292 | 113 | 32.03 | 25.43 | - |
| Liabilities | 9.42 | 13.11 | 13.42 | 10.55 | 20.53 | 17.24 | 14.85 | 25.34 | 15.75 | - |
| Book Value | 110 | 178 | 222 | 276 | 335 | 275 | 98.54 | -101 | -93.68 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Chimerix, Inc. |
| Country |
United States |
| Employees |
43 |
| CEO |
Michael A. Sherman |
Stock Information
| Ticker Symbol |
CMRX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CMRX |
| IPO Date |
April 11, 2013 |
Description
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.